Document resource
Background The significant mortality risk of epilepsy is partly driven by status epilepticus (SE). Pharmaceutical rescue therapies, such as buccal midazolam (BM), aim to terminate SE. This survey evaluates UK-based healthcare professionals’ clinical practice and experience in prescribing community-based rescue therapies.Methods A 21 item questionnaire composed of Likert-style and free-text questions was distributed through a non-discriminative snow-balling methodology to Epilepsy Specialist Nurses’ Association (ESNA) and the British International League Against Epilepsy (ILAE) members. Quantitative analysis used Chi-squared, Fishers’ exact and Mann-Whitney tests. Qualitative data were analysed through NVivo 14 software, following Braun and Clarke methodology.Results 86 participants (nurses n=64, doctors n=21) responded, indicating guideline-concordant use of emergency management plans and BM as a first-choice therapy for tonic-clonic seizures in SE. However, significant differences (P < 0.05) emerged between doctors and nurses in prescribing practices, including maximum dose, withdrawal strategies and use in multimorbid patients. Qualitative analysis identified eight themes, including concerns regarding BM overuse, misuse and abuse by patients and carers.Conclusion This study highlights the need for evidence-based guidelines on BM use in multimorbid patients and deprescribing strategies. Furthermore, robust safeguarding protocols are needed to regulate BM’s misuse and abuse potential, supported by oncoming community-based technologies.mcaebride@outlook.com